Aromatase inhibition and experimental antitumor activity of FCE 24304, MDL 18962 and SH 489.

Abstract

Human placental aromatase inhibitory properties of FCE 24304, MDL 18962, SH 489 and 4-hydroxyandrostenedione (4-OHA) were compared. The compounds caused time-dependent enzyme inactivation with t1/2 values of 13.9, 13.1, 45.3 and 2.1 min and Ki values of 26.0, 0.7, 2.0 and 29.0 nM respectively. The antitumor activity of FCE 24304, MDL 18962 and SH 489 was studied on the DMBA-induced mammary tumor in rats, at daily s.c. doses of 10 and 50 mg/kg. FCE 24304 induced 30 and 73% regressions of established tumors, associated with 86 and 93% decrease in total ovarian aromatase activity. SH 489 and MDL 18962 did not affect tumor growth. FCE 24304, like 4-OHA, was shown to inhibit LH hypersection in castrated rats. A gonadotropin suppressive effect could contribute to the antitumor activity of aromatase inhibitors in intact DMBA-induced tumor bearing rats.

• Authors: E di Salle, G Briatico, D Giudici, G Ornati, T Zaccheo
• Journal: Journal of steroid biochemistry (J Steroid Biochem) Vol. 34 Issue 1-6 Pg. 431-4 ( 1989) ISSN: 0022-4731 [Print] England
• PMID: 2516584 (Publication Type: Journal Article)

Chemical References

• Androstadienes
• Antineoplastic Agents
• Aromatase Inhibitors
• Androstenedione
• 9,10-Dimethyl-1,2-benzanthracene
• atamestane
• Luteinizing Hormone
• Pargyline
• plomestane
• exemestane

Topics

• 9,10-Dimethyl-1,2-benzanthracene
• Androstadienes (pharmacology, therapeutic use)
• Androstenedione (analogs & derivatives, pharmacology, therapeutic use)
• Animals
• Antineoplastic Agents (therapeutic use)
• Aromatase Inhibitors
• Female
• Humans
• Luteinizing Hormone (blood, metabolism)
• Male
• Mammary Neoplasms, Experimental (drug therapy)
• Microsomes (enzymology)
• Orchiectomy
• Ovary (enzymology)
• Pargyline (analogs & derivatives, pharmacology, therapeutic use)
• Placenta (enzymology)
• Pregnancy
• Rats
• Rats, Inbred Strains
• Reference Values